Sharing Insight on Myeloma, CAR T, and More in San Francisco

By
Article

We visited San Francisco, California for a State of the Science Summit on Hematologic Malignancies. The meeting covered novel agents and combinations in lymphoma, updates in acute and chronic leukemias, and modalities in the management of multiple myeloma.

We visited San Francisco, California for a State of the Science SummitTM on Hematologic Malignancies. The meeting covered novel agents and combinations in lymphoma, updates in acute and chronic leukemias, and modalities in the management of multiple myeloma.

Recent Videos
Michael Flanagan, PhD, chief scientific officer at Avidity
David Barrett, JD, the chief executive officer of ASGCT
David-Alexandre C. Gros, MD, Eledon’s chief executive officer
David Barrett, JD, the chief executive officer of ASGCT
Alfred L. Garfall, MD, MS, associate professor of medicine (hematology-oncology) and director, Autologous Hematopoietic Cell Transplantation, Cell Therapy and Transplant Program, Hospital of the University of Pennsylvania; and section chief, Multiple Myeloma, Division of Hematology/Oncology, Department of Medicine, Perelman School of Medicine, University of Pennsylvania,
Reena Sharma, MD, an adult metabolic consultant at Salford Royal Hospital
Nirav Shah, MD, MSHP, associate professor of medicine, at the Medical College of Wisconsin
Bhagirathbhai R. Dholaria, MD, an associate professor of medicine in malignant hematology & stem cell transplantation at Vanderbilt University Medical Center
Reena Sharma, MD, an adult metabolic consultant at Salford Royal Hospital
Mark Hamilton, MD, PhD, a hematology-oncology and bone marrow transplant (BMT) cell therapy fellow at Stanford University
Related Content
Donovan Decker, recipient of the 2025 MDA Legacy Award for Community Impact and Research

Donovan Decker’s Journey in Gene Therapy and Advocacy for LGMD—Breaking Barriers

Donovan Decker;Marco Meglio
March 24th 2025
Article

Donovan Decker, recipient of the 2025 MDA Legacy Award for Community Impact and Research, discussed his powerful journey as a patient advocate and gene therapy pioneer, shedding light on challenges and progress in LGMD.

ImmunoLogic

ImmunoLogic, Episode 2: "Charting New Frontiers in CAR T-Cell Safety" With Bruce Levine, PhD

Joseph A. Fraietta, PhD;Janna Minehart, MD;Noah Stansfield;Matt Hoffman
March 11th 2025
Podcast

In Episode 2 of ImmunoLogic, Bruce Levine, PhD, discussed the current the risk-benefit-ratio for CAR-T therapy.

Michael Flanagan, PhD, the chief scientific officer at Avidity

Del-Zota for Duchenne Muscular Dystrophy

Michael Flanagan, PhD;Noah Stansfield;Marco Meglio
March 23rd 2025
Article

Michael Flanagan, PhD, the chief scientific officer at Avidity, discussed the function and mechanism of the investigational antisense treatment, which is in development for DMD amenable to exon 44 skipping.

ImmunoLogic

ImmunoLogic, Episode 1: "Chemo-Free Lymphoma? Seriously?" With Stephen J. Schuster, MD

Joseph A. Fraietta, PhD;Janna Minehart, MD;Noah Stansfield;Matt Hoffman
January 31st 2025
Podcast

In Episode 1 of ImmunoLogic, Stephen J. Schuster, MD, discussed the potential of treating lymphoma without chemotherapy.

Multiple Sclerosis Awareness Month 2025: Looking Back at Progress for Cell Therapy

Multiple Sclerosis Awareness Month 2025: Looking Back at Progress for Cell Therapy

CGTLive Staff
March 21st 2025
Article

In observance of Multiple Sclerosis Awareness Month, held annually in March, we took a look back at the past year's news in cell therapy for MS.

FDA Approves Alnylam’s Vutrisiran for the Treatment of ATTR Amyloidosis With Cardiomyopathy

FDA Approves Alnylam’s Vutrisiran for the Treatment of ATTR Amyloidosis With Cardiomyopathy

Noah Stansfield
March 20th 2025
Article

The product is marketed under the name Amvuttra.

© 2025 MJH Life Sciences

All rights reserved.